攝護腺癌臨床特性與Ki-67表現之相關性

劉品均、林益聖、歐宴泉、許兆畬、童敏哲

童綜合醫院 泌尿科

The association between Ki-67 expression and characteristics of prostate cancer

Liu Pin-Chun, Lin Yi-Sheng, Ou Yen-Chuan, Shu Chao-Yu, Tung Min-Che

Division of Urology, Department of Surgery, Tungs’ Taichung Metroharbor Hospital, Taichung, Taiwan

Purpose:

Ki-67 had been widely used for assessment of proliferative activity in breast cancer. Ki-67 is often considered a marker of cellular proliferation and guides the decision of treatment choice. Ki-67 is a prognostic biomarker in localized prostate cancer. The purpose of this study was to explore the association of Ki-67 expression and prostate cancer clinicopathologic characteristics.

Materials and Methods:

We divided patients who diagnosed with prostate adenocarcinoma between 2018 to 2020 into two groups by Ki-67 labeling index (Ki67-LI) level. Post-operative outcomes and baseline characteristics were collected and analyzed by Wilcoxon rank sum test and Fisher's exact test under SPSS software.

Results:

There were a total of 9 patients reviewed and analyzed in this study. 2 had Ki67-LI ≥30% (Ki-67 high group), 7 had Ki67-LI ≤10% (Ki-67 low group). There was no difference between baseline data such as age and BMI. Among the Ki-67 high group, there was no significant difference in preoperative PSA level, tumor percentage, prostate grade group and the existence of angiolymphatic invasion when compared with the Ki-67 low group.

Conclusion:

This retrospective study shows there was no association of clinicopathologic characteristics of prostate cancer and the expression of Ki-67. The clinical and pathological characteristics cannot predict the expression of Ki-67.